EIGER BIOPHARMACEUTICALS INC's ticker is EIGR and the CUSIP is 28249U105. A total of 100 filers reported holding EIGER BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,998 | -78.9% | 29,498 | -51.4% | 0.00% | – |
| Q2 2023 | $42,724 | -35.1% | 60,688 | -17.3% | 0.00% | – |
| Q1 2023 | $65,831 | -93.3% | 73,399 | -91.1% | 0.00% | – |
| Q4 2022 | $978,194 | -73.6% | 828,977 | +68.6% | 0.00% | -100.0% |
| Q3 2022 | $3,702,000 | -34.5% | 491,786 | -45.2% | 0.00% | 0.0% |
| Q2 2022 | $5,652,000 | -52.1% | 897,213 | -36.9% | 0.00% | -50.0% |
| Q1 2022 | $11,805,000 | +441.3% | 1,422,278 | +238.5% | 0.00% | – |
| Q4 2021 | $2,181,000 | +198.8% | 420,149 | +284.8% | 0.00% | – |
| Q3 2021 | $730,000 | -25.9% | 109,174 | -5.5% | 0.00% | – |
| Q2 2021 | $985,000 | +103.9% | 115,488 | +111.4% | 0.00% | – |
| Q1 2021 | $483,000 | +64.8% | 54,618 | +128.9% | 0.00% | – |
| Q4 2020 | $293,000 | +614.6% | 23,865 | +376.2% | 0.00% | – |
| Q3 2020 | $41,000 | -84.5% | 5,012 | -81.8% | 0.00% | – |
| Q2 2020 | $264,000 | +103.1% | 27,500 | +43.6% | 0.00% | – |
| Q1 2020 | $130,000 | -75.5% | 19,152 | -46.1% | 0.00% | – |
| Q4 2019 | $530,000 | +395.3% | 35,536 | +242.2% | 0.00% | – |
| Q3 2019 | $107,000 | -33.5% | 10,386 | -31.5% | 0.00% | – |
| Q2 2019 | $161,000 | -81.4% | 15,169 | -75.5% | 0.00% | – |
| Q1 2019 | $867,000 | +61.2% | 62,026 | +17.3% | 0.00% | – |
| Q4 2018 | $538,000 | +323.6% | 52,880 | +399.5% | 0.00% | – |
| Q3 2018 | $127,000 | -63.4% | 10,587 | -62.7% | 0.00% | – |
| Q2 2018 | $347,000 | +9.8% | 28,405 | -11.6% | 0.00% | – |
| Q1 2018 | $316,000 | +79.5% | 32,150 | +154.8% | 0.00% | – |
| Q4 2017 | $176,000 | +6.0% | 12,619 | -16.5% | 0.00% | – |
| Q3 2017 | $166,000 | +33.9% | 15,119 | -3.6% | 0.00% | – |
| Q2 2017 | $124,000 | -1.6% | 15,681 | +43.0% | 0.00% | – |
| Q1 2017 | $126,000 | -55.3% | 10,968 | -54.8% | 0.00% | – |
| Q4 2016 | $282,000 | +2463.6% | 24,266 | +2698.8% | 0.00% | – |
| Q3 2016 | $11,000 | +450.0% | 867 | +767.0% | 0.00% | – |
| Q2 2016 | $2,000 | -88.2% | 100 | -90.0% | 0.00% | – |
| Q1 2016 | $17,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Telemetry Investments, L.L.C. | 135,848 | $2,024,000 | 6.74% |
| INTERWEST VENTURE MANAGEMENT CO | 764,918 | $11,397,000 | 4.91% |
| Knoll Capital Management, LLC | 350,238 | $5,219,000 | 3.85% |
| 683 Capital Management, LLC | 1,850,000 | $27,565,000 | 3.15% |
| Soleus Capital Management, L.P. | 205,407 | $3,060,000 | 2.95% |
| Broadfin Capital, LLC | 1,236,368 | $18,422,000 | 2.47% |
| P.A.W. CAPITAL CORP | 144,000 | $2,146,000 | 2.29% |
| MANGROVE PARTNERS IM, LLC | 847,284 | $12,625,000 | 1.85% |
| Corriente Advisors, LLC | 203,898 | $3,038,000 | 1.63% |
| Trellus Management Company, LLC | 63,850 | $951,000 | 1.59% |